Skip to content
PsychedeliaDokholyan Laboratory
Plate 461 of 545Verified

Nabilone

Also known asCesamet · Nabilona · Nabilonum · A04AD11 · Nabilonum [Latin] · Nabilona [Spanish] · (-)-Nabilone · Cesamet (TN)

(6aR,10aR)-1-hydroxy-6,6-dimethyl-3-(2-methyloctan-2-yl)-7,8,10,10a-tetrahydro-6aH-benzo[c]chromen-9-one

PubChem CID
5284592
Measurements
1
InChIKey
GECBBEABIDMGGL-RTBURBONSA-N

I · Summary

What is known

Published passages, each quoted whole and attributed to the database that published it. Two blocks are written here rather than quoted, and both say so where they stand: the synthesized summary at the top, which may draw only on the passages beneath it, and the history note, which cites the works it came from. Every claim in either carries a marker to its source.

What it is

  • Nabilone is a DEA Schedule II controlled substance. Substances in the DEA Schedule II have a high potential for abuse which may lead to severe psychological or physical dependence. It is a Hallucinogenic substances substance.

    Drug Enforcement Administration (DEA)

  • Nabilone (marketed as Cesamet) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). Although structurally distinct from THC, nabilone mimics THC's structure and pharmacological activity through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, however it is considered to be twice as active as Δ⁹-THC. Nabilone is approved by the FDA for the treatment of nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments. Tetrahydrocannabinol (THC) and cannabidiol (CBD) are the two most abundant cannabinoids fo…

    DrugBank

  • Nabilone is an orally available cannabinoid agonist that is used to treat chemotherapy induced nausea and vomiting and to stimulate appetite, particularly in patients with wasting disease or cachexia. Nabilone is associated with a minimal rate of serum enzyme elevations during therapy and has not been linked to cases of clinically apparent liver injury with jaundice.

    LiverTox

  • Nabilone is a synthetic cannabinoid and dibenzopyrane derivative with anti-emetic activity. Although the mechanism of action has not been fully elucidated yet, it has been suggested that nabilone is a highly selective and strong agonist for the cannabinoid receptors CB1 and CB2, both of which are coupled to Gi/o proteins. The CB1 receptors are expressed predominantly in central and peripheral neurons and receptor stimulation has been implicated in the reduction of chemotherapy-induced nausea.

    NCI Thesaurus (NCIt)

Recognized use

  • Nabilone is indicated for the treatment of the nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments. This restriction is required because a substantial proportion of any group of patients treated with Nabilone can be expected to experience disturbing psychotomimetic reactions not observed with other antiemetic agents.

    DrugBank

How it acts

  • Nabilone is an orally active synthetic cannabinoid which, like other cannabinoids, has complex effects on the central nervous system (CNS). It has been suggested that the antiemetic effect of nabilone is caused by interaction with the cannabinoid receptor system, i.e., the CB (1) receptor, which is a component of the endocannabinoid system of the body. The endocannabinoid system is widely distributed throughout the central and peripheral nervous system (via the Cannabinoid Receptors CB1 and CB2) and plays a role in many physiological processes such as inflammation, cardiovascular function, learning, pain, memory, stress and emotional regulation, and the sleep/wake cycle among many others.…

    DrugBank

  • Nabilone is a cannabinoid with therapeutic uses. It is an analog of dronabinol (also known as tetrahydrocannabinol or THC), the psychoactive ingredient in cannabis. Although structurally distinct from THC, nabilone mimics THC's structure and pharmacological activity through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, however it is considered to be twice as active as Δ⁹-THC.

    DrugBank

Behavior carries the pharmacological classes and the acute-effect durations, with plasma half-life kept separate from duration of effect.

In the body

  • Nabilone appears to be completely absorbed from the human gastrointestinal tract when administered orally. Following oral administration of a 2 mg dose of radiolabeled nabilone, peak plasma concentrations of approximately 2 ng/mL nabilone and 10 ng equivalents/mL total radioactivity are achieved within 2.0 hours.

    Absorption, Distribution and Excretion

    DrugBank

  • The route and rate of the elimination of nabilone and its metabolites are similar to those observed with other cannabinoids, including delta-9-THC (dronabinol). When nabilone is administered intravenously, the drug and its metabolites are eliminated mainly in the feces (approximately 67%) and to a lesser extent in the urine (approximately 22%) within 7 days. Of the 67% recovered from the feces, 5% corresponded to the parent compound and 16% to its carbinol metabolite. Following oral administration about 60% of nabilone and its metabolites were recovered in the feces and about 24% in urine. Therefore, it appears that the major excretory pathway is the biliary system.

    Absorption, Distribution and Excretion

    DrugBank

  • The apparent volume of distribution of nabilone is about 12.5 L/kg.

    Absorption, Distribution and Excretion

    DrugBank

  • Hepatic. Two metabolic pathways have been suggested. The major pathway probably involves the direct oxidation of Nabilone to produce hydroxylic and carboxylic analogues. These compounds are thought to account for the remaining plasma radioactivity when carbinol metabolites have been extracted.

    Metabolism/Metabolites

    DrugBank

History, discovery and cultural use

— Not in this archive. PubChem, ChEMBL and the Human Protein Atlas publish pharmacology, regulation and toxicology, and none of them publishes a heading for when Nabilone was first made, by whom, or how it has been used. That is a gap in the databases this site reads and not a gap in the literature — the history of these compounds is written, at length and under peer review, in the works below. This site does not summarize them; it says where they are. Where a published passage above happens to touch origin or traditional use, it appears inside the entry that carries it.

Histories of this field

Scholarship on psychedelics generally, not on Nabilone specifically. Whether any of these treats this compound is a question for the book, not for this page.

  • Mescaline: A Global History of the First Psychedelic

    Traces mescaline and the peyote and San Pedro cacti from pre-Columbian ritual use through nineteenth-century chemistry to twentieth-century psychiatry and the counterculture.

    Jay M. Mescaline: A Global History of the First Psychedelic. Yale University Press, New Haven and London; 2019. ISBN 9780300231076.

  • Expanding Mindscapes: A Global History of Psychedelicsopen access

    Essays on the international and cross-cultural history of psychedelic science, deliberately decentring the standard North American and European account.

    Dyck E, Elcock C, editors. Expanding Mindscapes: A Global History of Psychedelics. The MIT Press, Cambridge MA; 2023. ISBN 9780262546935 (paper), 9780262376891 (open access). doi:10.7551/mitpress/14417.001.0001.

  • Plants of the Gods: Their Sacred, Healing, and Hallucinogenic Powers

    Botany, ethnography and chemistry of the principal hallucinogenic plants, by the founder of modern ethnobotany and the chemist who first synthesized LSD.

    Schultes RE, Hofmann A, Rätsch C. Plants of the Gods: Their Sacred, Healing, and Hallucinogenic Powers. 2nd ed. Healing Arts Press, Rochester VT; 2001. ISBN 9780892819799.

  • Psychonauts: Drugs and the Making of the Modern Mind

    The tradition of scientific self-experimentation with psychoactive drugs, and its part in the emergence of psychology and of modernism.

    Jay M. Psychonauts: Drugs and the Making of the Modern Mind. Yale University Press, New Haven; 2023. ISBN 9780300257946.

  • Ancient Psychoactive Substances

    Archaeological and bioarchaeological evidence for psychoactive plant use across the ancient world.

    Fitzpatrick SM, editor. Ancient Psychoactive Substances. University Press of Florida, Gainesville; 2018. ISBN 9780813056708.

  • History and Current Status of Psychedelics and Entactogens for the Treatment of Psychiatric Disorders

    A chapter tracing psychedelic and entactogen research from earlier ritual use through the mid-century research period to current clinical trials.

    Stroud C, Posey Norris SM, Matney C, editors. History and Current Status of Psychedelics and Entactogens for the Treatment of Psychiatric Disorders. In: Exploring Psychedelics and Entactogens as Treatments for Psychiatric Disorders: Proceedings of a Workshop. National Academies Press, Washington DC; 2022. NBK587225.

    Workshop proceedings record what participants said; they are not a consensus statement of the National Academies.

  • Pharmacokinetic and Pharmacodynamic Aspects of Peyote and Mescaline: Clinical and Forensic Repercussions

    Peer-reviewed review covering the isolation, synthesis, pharmacology and ritual use of peyote and mescaline.

    Dinis-Oliveira RJ, Pereira CL, da Silva DD. Pharmacokinetic and Pharmacodynamic Aspects of Peyote and Mescaline: Clinical and Forensic Repercussions. Current Molecular Pharmacology 12(3):184–194; 2019. doi:10.2174/1874467211666181010154139.

Institutional archives

  • Heffter Research Institute Funds and coordinates clinical research on psilocybin, and keeps records of the studies it has supported since 1993. Sponsors the research it archives.
  • Multidisciplinary Association for Psychedelic Studies (MAPS) Sponsors clinical research, chiefly on MDMA-assisted therapy, and publishes an archive of historical and contemporary documents. A sponsor and an advocacy organization, not a disinterested archive; its clinical programme has a commercial arm.

The rest of this dossier

  • Affinity — 1 measurement in this archive, equilibrium constants kept apart from functional readouts.
  • Toxicology — 1 published passage, plus any assay in this archive bearing on toxicity.
  • Legal — DEA Schedule II, with the passage it was read from.
  • Systems — where this compound’s targets are transcribed, by brain region and tissue.

Passages via PubChem descriptive sections, aggregating DrugBank, LiverTox, FDA, DEA, HSDB, EPA. Each is quoted whole and attributed to the database that published it. The only prose written here about Nabilone is the history note, which says so on its face and carries a reference for every claim in it.

II · Identity

Structure and descriptors

Descriptors are computed here with RDKit from the structure PubChem returns — not from the archive's stored copy, so an edited local structure cannot reach this table.

2D structural depiction of Nabilone
Depiction served by PubChem for CID 5284592. Not redrawn here, so the picture and the identity come from the same record.
Formula
C24H36O3R
Molecular weight
372.55g/molR
Exact mass
372.2664DaR
cLogP
6.26R
TPSA
46.5ŲR
H-bond donors
1R
H-bond acceptors
3R
Rotatable bonds
6R
Aromatic rings
1R
Heavy atoms
27R
Fraction sp³
0.708R
Formal charge
0R

Computed with RDKit 2025.09.2 from the SMILES returned by PubChem. Audit run 26/09/2026.

Bemis–Murcko scaffold

O=C1CC[C@H]2COc3ccccc3[C@@H]2C1

No other compound in this archive shares it. All families

III · Behavior

Behavioral summary

Class, mechanism, and the duration of acute effects — each quoted from the record or trial that publishes it. Duration of effects and plasma half-life are shown separately, because they are different quantities and diverge by a factor of three or four.

Classification

Duration of acute subjective effects

—

No controlled human trial reporting a duration for this compound is cited here. The archive holds no other record of one either. A duration is not inferred from a chemical relative.

Plasma elimination half-life

How fast the body clears the drug — not how long the effects last. The two diverge sharply: LSD is cleared with a half-life of about 2.6 h while its subjective effects run 8–12 h.

  • The plasma half-life (T1/2) values for nabilone and total radioactivity of identified and unidentified metabolites are about 2 and 35 hours, respectively.
    DrugBank

Primary pharmacological drivers

ChEMBL holds no curated mechanism-of-action record for this compound. The measured affinities below are the evidence this archive has for what it binds.

Mechanism, as published

Quoted verbatim from the database named after each passage, never summarized.

  • Nabilone is an orally active synthetic cannabinoid which, like other cannabinoids, has complex effects on the central nervous system (CNS). It has been suggested that the antiemetic effect of nabilone is caused by interaction with the cannabinoid receptor system, i.e., the CB (1) receptor, which is a component of the endocannabinoid syste…
    DrugBank
  • Nabilone is a cannabinoid with therapeutic uses. It is an analog of dronabinol (also known as tetrahydrocannabinol or THC), the psychoactive ingredient in cannabis. Although structurally distinct from THC, nabilone mimics THC's structure and pharmacological activity through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabi…
    DrugBank

IV · Clinical

Clinical description

Where this compound's substance class sits in ICD-11 and DSM-5-TR, and how much of the recorded literature speaks to each domain of a mental status examination.

No diagnostic chapter is shown for this compound. Either PubChem records no MeSH pharmacological class for it, or the class it records is not one of the substance classes ICD-11 gives a chapter to. Inferring a chapter from the compound’s name or its binding profile would be a diagnosis this archive is in no position to make.

How much has been written about each domain

The clinical domains, and how many of the records this archive holds for this compound say something under each. What the terms mean, and the word list behind every spoke, are set out in the method.

Affect0Mood0Perception0Cognition1Thought process0Thought content0Psychomotor activity0Insight and judgment0
This measures the literature, not the compound. Each spoke counts how many of the 4 records this archive holds for this compound say something under that domain — 1 at the widest ring. A long spoke means the subject has been written about, not that the effect is strong, and a spoke at the center means nothing here discusses it rather than that nothing happens. The terms behind each domain are listed in the method.
Cognition 1
matched on “memory” · in Pharmacology: Mechanism of Action

V · Systems

Systems physiology

Where the targets this compound binds are transcribed — brain regions on the left, peripheral and autonomic tissues on the right. A join of two measurements, not a claim about what the compound does to either.

Brain

cerebral cortex — 18.6 nTPM, from CNR1cerebellum — 18.3 nTPM, from CNR1hippocampal formation — 13.2 nTPM, from CNR1amygdala — 13.3 nTPM, from CNR1hypothalamus — 9.0 nTPM, from CNR1thalamus — no resolved target expressed herebasal ganglia — 15.1 nTPM, from CNR1medulla oblongata — no resolved target expressed here

basal ganglia: drawn as the caudate nucleus, putamen and globus pallidus.

Measured but not drawn — this anatomogram has no outline for them: pituitary gland 17.3, midbrain 2.1, spinal cord 1.7, retina 1.1.

Body

heart — 0.8 nTPM, from CNR1smooth muscle — 2.3 nTPM, from CNR1lung — 2.8 nTPM, from CNR1liver — 0.1 nTPM, from CNR1kidney — 0.6 nTPM, from CNR1stomach — 3.4 nTPM, from CNR1duodenum — 0.6 nTPM, from CNR1small intestine — 8.1 nTPM, from CNR1colon — 10.0 nTPM, from CNR1adrenal gland — 4.6 nTPM, from CNR1thyroid gland — 3.9 nTPM, from CNR1pancreas — 1.2 nTPM, from CNR1urinary bladder — 3.4 nTPM, from CNR1skeletal muscle — 1.8 nTPM, from CNR1spleen — 1.4 nTPM, from CNR1salivary gland — 1.8 nTPM, from CNR1
019 nTPM

Square-root ramp · shared scale across both plates

Shading is transcript level — not affinity, and not affinity combined with expression. Outlined but unshaded organs hold none of this compound’s resolved targets above the atlas’s detection threshold. Anatomy from EMBL-EBI Anatomogram (Apache License 2.0); regions identified by Uberon (uberon.org), CC BY 3.0.

Brain regions

Regions where this compound's measured targets are transcribed. Linked from the plate above.

  1. cerebral cortex

    18.6 nTPM

  2. cerebellum

    18.3 nTPM

  3. pituitary gland

    17.3 nTPM

  4. basal ganglia

    15.1 nTPM

  5. amygdala

    13.3 nTPM

  6. hippocampal formation

    13.2 nTPM

  7. hypothalamus

    9.0 nTPM

  8. midbrain

    2.1 nTPM

  9. spinal cord

    1.7 nTPM

  10. retina

    1.1 nTPM

Peripheral & autonomic

Tissues outside the CNS expressing the same targets — where a compound's bodily effects become possible.

  1. colon

    10.0 nTPM

  2. small intestine

    8.1 nTPM

  3. adrenal gland

    4.6 nTPM

  4. thyroid gland

    3.9 nTPM

  5. stomach 1

    3.4 nTPM

  6. urinary bladder

    3.4 nTPM

  7. lung

    2.8 nTPM

  8. smooth muscle

    2.3 nTPM

  9. skeletal muscle

    1.8 nTPM

  10. salivary gland

    1.8 nTPM

  11. spleen

    1.4 nTPM

  12. pancreas

    1.2 nTPM

  13. heart muscle

    0.8 nTPM

  14. kidney

    0.6 nTPM

  15. duodenum

    0.6 nTPM

  16. liver

    0.1 nTPM

Each row joins two published measurements and nothing else: the affinity this archive holds for the compound at that target, and the transcript level the Human Protein Atlas reports for that target’s gene in that region. Bars scale with expression only. Expression is not activation — a receptor transcribed in a region is a receptor available to be bound there, which is a weaker and more defensible claim than saying the region is affected.

Expression data from Human Protein Atlas (CC BY-SA 3.0), RNA expression, nTPM (normalized transcripts per million), consensus tissue dataset. Uhlén M, et al. Tissue-based map of the human proteome. Science. 2015;347(6220):1260419.

VI · Profile

Affinity rosette

The strongest measurement at each of 1 molecular targets. Cell-line and whole-organism screens are excluded here — they carry no affinity — and appear in the table below.

CB1 — Ki 7.65 pXCB1579
Fig. Radius is pX = −log₁₀(value in M), that is 9 − log₁₀(value in nM), computed from the normalized measurement. Hatched wedges are equilibrium binding constants (Ki, Kd); dashed outlines are functional readouts (IC₅₀, EC₅₀, AC₅₀, potency), which answer a different question and are not pooled with them. Rings mark whole pX units from 5 to 10, labeled every second ring in the gutter at the top. Where a target carries several measurements, the strongest is drawn.

VII · Toxicology

Toxicological profile

What has been measured, and what has been published — kept apart, and neither scored. There is no risk rating on this page; the archive once carried one, identical for every compound, produced by a stub.

Measured in this archive

Assays that bear on toxicity, drawn from the same ChEMBL records as everything else on this page. They are measurements of what a compound binds or does to cells — not verdicts about what it does to a person.

No hERG, cytochrome, cytotoxicity or transport measurement exists for Nabilone in this archive.

As published

Quoted verbatim from the database named after each passage, never summarized — a summary of a toxicology statement is a new claim.

Hepatotoxicity

  • Serum aminotransferase elevations during nabilone therapy are not common, generally mild and similar to the rate in controls who are receiving cancer chemotherapy. There have been no convincing cases of clinically apparent liver injury attributable to nabilone published in the literature and, thus, significant liver injury from nabilone must be exceeding rare, if it occurs at all.

    LiverTox

Published passages via PubChem toxicology sections, aggregating Hazardous Substances Data Bank (HSDB), RTECS, LiverTox. No figure on this page is scored, ranked or combined into a risk level.

VIII · Evidence

Every measurement

One row per published value. The identifier in the last column resolves to the ChEMBL assay record it was read from.

Equilibrium binding constants 1

Ki and Kd — a concentration at equilibrium. Directly comparable across rows at the same target.

TargetClassTypeValue (nM)pXOrganismAssay
CB1Cannabinoid receptorsKi22.307.65RATPMID 8474008
P
PubChem
C
ChEMBL
R
Computed here with RDKit
D
Derived here from the stored measurement

IX · Trials

Registered clinical trials

Studies filed with ClinicalTrials.gov that name this compound as an intervention. A registered trial is a protocol, not a result — status and enrollment are printed beside every row, and withdrawn studies are counted rather than hidden.

34T

Registered studies

2T

Open or ongoing

33T

With a phase recorded

By phase

A study may carry two phase codes at once, so these count studies bearing each phase and do not sum to the total.

  • Phase 15
  • Phase 217
  • Phase 39
  • Phase 46
  • Not applicable2

By status

The registry’s own status for each record. Withdrawn and terminated studies are counted here rather than hidden — a stopped trial is part of what is known.

  • Completed22
  • Unknown status4
  • Terminated4
  • Recruiting2
  • Withdrawn2

The 25 most recently started, of 34

Newest first by start date. Each identifier opens the registry record it came from; the title is the sponsor’s own, quoted.

  • NCT07644052Recruiting · Phase 3

    Efficacy of PP-01 in Mitigating Cannabis Withdrawal Symptoms in Adults With Cannabis Use Disorder

    Enrollment
    420Testimated
    Started
    2026-06-17
    Sponsor
    PleoPharma, Inc.

    Conditions Cannabis Withdrawal

    Matched “Nabilone” in the study’s intervention “Nabilone”

  • NCT03422861Unknown status · Not applicable

    Nabilone Use For Acute Pain in Inflammatory Bowel Disease Patients

    Enrollment
    80Testimated
    Started
    2023-12
    Sponsor
    Samuel Lunenfeld Research Institute, Mount Sinai Hospital

    Conditions Inflammatory Bowel Diseases

    Matched “Nabilone” in the study’s intervention “Nabilone”

  • NCT05885685Completed · Phase 4

    Investigating the Effects of Nabilone on Endocannabinoid Metabolism

    Enrollment
    10Tactual
    Started
    2023-10-31
    Sponsor
    Centre for Addiction and Mental Health

    Conditions Healthy

    Matched “Nabilone” in the study’s intervention “Nabilone Oral Capsule”

  • NCT05742698Terminated · Phase 2

    Nabilone for Agitation in Frontotemporal Dementia

    Enrollment
    3Tactual
    Started
    2023-03-07
    Sponsor
    Simon Ducharme, MD

    Conditions Frontotemporal Dementia · Frontotemporal Dementia, Behavioral Variant · Primary Progressive Aphasia · bvFTD · PPA · FTD

    Matched “Nabilone” in the study’s intervention “Nabilone”

  • NCT04057456Completed · Phase 3

    Cannabinoids and an Anti-inflammatory Diet for the Treatment of Neuropathic Pain After Spinal Cord Injury

    Enrollment
    14Tactual
    Started
    2023-03-01
    Sponsor
    Eldon Loh, MD

    Conditions Spinal Cord Injuries · Neuropathic Pain

    Matched “Nabilone” in the study’s intervention “Nabilone Capsules”

  • NCT05494437Completed · Phase 2

    Effect of PP-01 on Cannabis Withdrawal Syndrome

    Enrollment
    234Tactual
    Started
    2022-10-27
    Sponsor
    PleoPharma, Inc.

    Conditions Cannabis Withdrawal

    Matched “Nabilone” in the study’s intervention “Nabilone”

  • NCT05180968Completed · Phase 3

    DIalysis Symptom COntrol-Pruritus Outcome Trial

    Enrollment
    14Tactual
    Started
    2022-08-02
    Sponsor
    University of Manitoba

    Conditions End Stage Renal Disease · Pruritus

    Matched “Nabilone” in the study’s intervention “Nabilone 0.5 MG Oral Capsule”

  • NCT05273320Completed · Phase 1

    Clinical Trial of Nabilone for Aggression in Adults With Intellectual and Developmental Disabilities

    Enrollment
    20Tactual
    Started
    2022-03-17
    Sponsor
    Hsiang-Yuan Lin

    Conditions Intellectual Disability · Developmental Disability · Aggression · Behavior Problem

    Matched “Nabilone” in the study’s intervention “Nabilone”

  • NCT04880278Withdrawn · Phase 1 / Phase 2

    Multimodal Assessment of Cannabinoid Target Engagement in Adults With Obsessive-Compulsive Disorder

    Enrollment
    0Tactual
    Started
    2022-03-01
    Sponsor
    New York State Psychiatric Institute

    Conditions Obsessive-Compulsive Disorder

    Matched “Nabilone” in the study’s intervention “Nabilone”

  • NCT04801641Terminated · Phase 2

    A Pilot Trial of Nabilone for the Treatment of Obesity

    Enrollment
    18Tactual
    Started
    2021-09-17
    Sponsor
    Centre for Addiction and Mental Health

    Conditions Obesity

    Matched “Nabilone” in the study’s intervention “Nabilone”

  • NCT04807829Withdrawn · Phase 2

    Adjunctive CB1 Agonist Nabilone in Inpatients With Active Suicidal Ideation

    Enrollment
    0Tactual
    Started
    2021-04
    Sponsor
    The University of Texas Health Science Center, Houston

    Conditions Suicidal Ideation

    Matched “Nabilone” in the study’s intervention “Nabilone”

  • NCT04516057Recruiting · Phase 3

    Nabilone for Agitation Blinded Intervention Trial

    Enrollment
    112Testimated
    Started
    2021-02-01
    Sponsor
    Sunnybrook Health Sciences Centre

    Conditions Alzheimer Disease · Agitation

    Matched “Nabilone” in the study’s intervention “Nabilone”

  • NCT03773796Completed · Phase 3

    Nabilone for Non-motor Symptoms in Parkinson's Disease

    Enrollment
    22Tactual
    Started
    2018-08-06
    Sponsor
    Medical University Innsbruck

    Conditions Parkinson Disease

    Matched “Nabilone” in the study’s intervention “Nabilone 0.25 mg”

  • NCT03769896Completed · Phase 2

    Nabilone for Non-motor Symptoms in Parkinson's Disease

    Enrollment
    48Tactual
    Started
    2017-10-03
    Sponsor
    Medical University Innsbruck

    Conditions Parkinson Disease

    Matched “Nabilone” in the study’s intervention “Nabilone 0.25 mg”

  • NCT02911324Completed · Phase 1 / Phase 2

    Cannabinoid Medication for Adults With OCD

    Enrollment
    16Tactual
    Started
    2016-09
    Sponsor
    New York State Psychiatric Institute

    Conditions Obsessive-Compulsive Disorder

    Matched “Nabilone” in the study’s intervention “Nabilone”

  • NCT03251326Terminated · Phase 1 / Phase 2

    Nabilone in Cannabis Users With PTSD

    Enrollment
    4Tactual
    Started
    2015-10
    Sponsor
    New York State Psychiatric Institute

    Conditions Cannabis · Post Traumatic Stress Disorder

    Matched “Nabilone” in the study’s intervention “Nabilone”

  • NCT02351882Completed · Phase 2 / Phase 3

    Safety and Efficacy of Nabilone in Alzheimer's Disease

    Enrollment
    38Tactual
    Started
    2015-01
    Sponsor
    Sunnybrook Health Sciences Centre

    Conditions Alzheimer Disease · Agitation · Weight Loss · Pain · Oxidative Stress

    Matched “Nabilone” in the study’s intervention “Nabilone”

  • NCT02802540Unknown status · Phase 2 / Phase 3

    Nabilone Effect on the Attenuation of Anorexia, Nutritional Status and Quality of Life in Lung Cancer Patients

    Enrollment
    78Testimated
    Started
    2014-12
    Sponsor
    Instituto Nacional de Cancerologia de Mexico

    Conditions Non-Small Cell Lung Cancer · Anorexia · Cachexia · Weight Lose

    Matched “Nabilone” in the study’s intervention “Nabilone”

  • NCT03210766Completed

    Nabilone and THC/CBD for the Treatment of FBSS Refractory Pain

    Enrollment
    20Tactual
    Started
    2014-09-01
    Sponsor
    Azienda Ospedaliera Universitaria Policlinico "G. Martino"

    Conditions FBSS

    Matched “Nabilone” in the study’s intervention “Nabilone”

  • NCT02115529Completed · Phase 2

    Study of Prevention of Postoperative Nausea and Vomiting Using Cesamet

    Enrollment
    331Tactual
    Started
    2014-04
    Sponsor
    Unity Health Toronto

    Conditions Postoperative Nausea and Vomiting

    Matched “Nabilone” in the study’s intervention “Nabilone”

  • NCT01222468Completed · Phase 2

    Effect of Cannabinoids on Spasticity and Neuropathic Pain in Spinal Cord Injured Persons

    Enrollment
    12Tactual
    Started
    2012-06
    Sponsor
    University of Manitoba

    Conditions Muscle Spasticity as a Result of Spinal Cord Injury

    Matched “Nabilone” in the study’s intervention “nabilone 0.5 mg”

  • NCT01517100Completed · Phase 1

    The Role of Endocannabinoids in Insulin Production and Action

    Enrollment
    45Tactual
    Started
    2012-01-05
    Sponsor
    National Institute on Aging (NIA)

    Conditions Healthy Volunteers

    Matched “Nabilone” in the study’s intervention “Nabilone”

  • NCT01347762Completed · Phase 2 / Phase 3

    Nabilone for Cannabis Dependence: A Pilot Study

    Enrollment
    84Tactual
    Started
    2010-06
    Sponsor
    Mclean Hospital

    Conditions Cannabis Dependence · Marijuana Dependence

    Matched “Nabilone” in the study’s intervention “Nabilone”

  • NCT00699634Completed · Phase 2

    Nabilone for the Treatment of Phantom Limb Pain

    Enrollment
    50Testimated
    Started
    2009-01
    Sponsor
    University of Manitoba

    Conditions Phantom Limb Pain · Neuropathic Pain

    Matched “Nabilone” in the study’s intervention “Nabilone”

  • NCT01035281Unknown status · Phase 3

    Efficacy Study of Nabilone in the Treatment of Diabetic Peripheral Neuropathic Pain

    Enrollment
    60Testimated
    Started
    2008-01
    Sponsor
    University of Calgary

    Conditions Diabetic Neuropathies

    Matched “Nabilone” in the study’s intervention “Nabilone, flexible dosing”

Records from ClinicalTrials.gov (U.S. National Library of Medicine, NIH), API v2. A study is listed against a compound only when a verified name for that compound appears as a whole word in one of the study's own intervention names. A short code must appear as written, and a name the registry uses for something else (Aleph, a vaccine maker) is not matched. Title matches are not accepted. The matched name and the intervention text it matched are shown with every row.

Searched as Nabilone · (-)-Nabilone. Run this search at the registry — it returns the unfiltered result, including studies this page rejected as belonging to a different molecule.

A registered trial is a protocol somebody filed with the registry. It is not a result, and nothing on this plate says whether Nabilone worked.

XI · Literature

Sources behind this dossier

The papers this compound's values were read from, ranked by what each contributed. Not a review of the field.

Every paper below is one some value on this page came from — a binding constant, a passage of pharmacology or toxicology, or a measured duration. Each entry says what this archive took from it. Nothing else is claimed about any of them: the title is the study’s own account of itself, and a summary written here would be an assertion with no source behind it.

  1. 01

    Cannabinoid structure-activity relationships: correlation of receptor binding and in vivo activities

    Compton DR, Rice KC, De Costa BR et al. · The Journal of pharmacology and experimental therapeutics 1993

    • · 1 measurement at 1 target (Ki), strongest CB1 at 7.65 pX

    PMID 8474008